Feature stories | Technology & innovation

Team outside Moscow works to bring about medicines of the future

2 Mar '22
Scientists at the Neutron Physics Laboratory, which is part of the Joint Institute for Nuclear Research (JINR) in Dubna outside Moscow, have developed what they refer to as biohybrid therapeutic nanocomplexes based on natural ingredients. The solution is reported to display antimicrobial and anti-cancer activity. The team hopes their research results may lay the foundation for the development in a near future of next gen drugs capable of overpowering bacteria that are highly impervious to current medication.

The problem

The goal of synthesizing a new generation of nanodimensional vehicles for target delivery of drugs has been viewed lately as a must-have for modern pharmacology. Such vehicles are expected to help solve the burning problem of vanquishing antibiotic-resistant germs and malignant tumors.

According to 2019 statistics published in the medical journal Lancet, as many as five million deaths that year were caused, in one way or another, by bacterial infections that are notorious for their insusceptibility to drugs. The World Health Organization believes cancer is responsible for every sixth death worldwide.

Synthetic medication solutions prevail in the market today; however, developers are increasingly setting sights on possible ways of substituting individual ingredients with purely natural substances or their derivatives. The latters key competitive advantage over synthetic ones is much lower toxicity; in fact, their impact on the human immune system may even be positive.

A solution

JINRs biocompatible hybrid nanocomplexes are based on green silver and silver chloride nanoparticles. To make those, the research team tapped the curative power of curcuma root extract and a blend of vine leaves and mint. Auxiliary components included soybean lecithin liposomes and chitosan.

The new nanocomplexes were tested for activity and reportedly showed strong enough antioxidant properties. Another test was anti-cancer efficiency monitoring. For some of the new systems their therapeutic index was one plus, meaning that their efficacy against tumorous cells was stronger than against healthy ones.

The JINR technology may be used across all stages of pharmacological research, the Dubna team said.
Oleg Kouzbit, managing editor: Im glad you join us here and take The Bridge walk for Marchmonts weekly review of the Russian regions innovative present and future. Stay close and youll find out more of how Russia is bridging the existing gap between its researchers and businesses.
Publish in Twitter
Write to Facebook
Google Buzz
Write to LiveJournal
Show in MM
Share MK
COMMENT ON THIS STORY
Find Related Content

Locations: Dubna; Moscow

Tags: cancer (71) / silver nanoparticles (2) / Joint Institute for Nuclear Research (1) / microbes (0) / biohybrid therapeutic nanocomplexes (0) /

Latest News: Feature stories
25 May '22 | Industry, manufacturing | Technology & innovation
29 Apr '22 | Technology & innovation
 
Search (News archive - 22990)
Technology Scouting Solutions For Industry
NATT
Advertising
Marchmont News

Latest News

27 Jun '22
Siberian scientists have developed new hybrid...
24 Jun '22
A new device, developed by a Russian start-up and...
22 Jun '22
Russian researchers have come up with a new Si...

Most read stories from last week

27 Jun '22
Siberian scientists have developed new hybrid...